The company finalized the sale of 33.5 million shares late Tuesday, marking a significant expansion from the original plan to offer 25 million shares. This surge in volume reflects strong market appetite for the firm’s pipeline, which now hits the public market under the ticker PBLS.

Beyond the primary offering, Parabilis secured an additional $75 million through a concurrent private placement. Long-term collaboration partner Regeneron Pharmaceuticals purchased approximately 4.2 million of those shares at $18 apiece. With the capital influx complete, trading is scheduled to commence Wednesday on the Nasdaq Global Select Market.